Diagnostic and prognostic value of stem cell factor plasma level in glioblastoma multiforme patients

Autor: Amirhosein Kefayat, Alireza Amouheidari, Fatemeh Ghahremani, Zahra Alirezaei
Rok vydání: 2021
Předmět:
Male
Oncology
Cancer Research
diagnosis
Stem cell factor
stem cell factor
c‐Kit
DNA Modification Methylases
Research Articles
RC254-282
Aged
80 and over
Receiver operating characteristic analysis
Plasma samples
Brain Neoplasms
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Middle Aged
Isocitrate Dehydrogenase
Progression-Free Survival
Tumor Burden
Preoperative Period
biomarker
Biomarker (medicine)
Female
Research Article
Adult
medicine.medical_specialty
Enzyme-Linked Immunosorbent Assay
Methylation
Diagnosis
Differential
glioblastoma multiforme
Internal medicine
Biomarkers
Tumor
medicine
Humans
Radiology
Nuclear Medicine and imaging
Aged
business.industry
Tumor Suppressor Proteins
Significant difference
Clinical Cancer Research
Plasma levels
medicine.disease
DNA Repair Enzymes
ROC Curve
Case-Control Studies
Potential biomarkers
Mutation
prognosis
Glioblastoma
business
Zdroj: Cancer Medicine, Vol 10, Iss 15, Pp 5154-5162 (2021)
Cancer Medicine
ISSN: 2045-7634
Popis: Background Investigation of novel blood‐circulating agents as potential biomarkers for glioblastoma multiforme (GBM) patients’ diagnosis and monitoring has gained lots of attention, due to limitations of imaging modalities and invasive tissue biopsy procedures. The present study aims to assess the diagnostic and prognostic values of preoperative stem cell factor (SCF) plasma level in GBM patients. Methods Preoperative plasma samples from 58 GBM patients and 20 patients with nonglial tumors and 30 healthy controls were obtained. SCF levels were measured by employing the enzyme‐linked immunosorbent assay test and the values were compared between these three groups. Then, the association of SCF plasma level and tumor volume, progression‐free survival (PFS), and overall survival (OS) for the GBM patients were evaluated. Results Mean preoperative SCF plasma level of the GBM patients (2.80 ± 1.52 ng/ml) was significantly higher (p
This study suggests that measurement of the SCF plasma level can aid in GBM patient's management for diagnostic purposes and as an efficient diagnostic plasma biomarker in patients with a new brain mass to differentiate between glioblastoma and nonglial tumors. However, this plasma biomarker does not exhibit prognostic value.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje